IL33 and Hepatic steatosis: When fed with MCD or HFD, treatment with IL-33 attenuated hepatic steatosis (Figure 7a and Figure 8a) and reduced hepatic triglyceride levels (Figure 7b and Figure 8b) and serum ALT levels (Figure 7c and Figure 8c) in wild-type mice, but had no significant effect on hepatic steatosis, hepatic triglyceride levels and serum ALT levels in ST2 knockout mice.